Raise Capital
Products
Resources
DealMaker co-founders finalists for EY Entrepreneur Of The Year® 2022
May 25, 2022
Toronto, Ontario | May 25, 2022 09:00 AM, Eastern
DealMaker is delighted to announce that co-founders Rebecca Kacaba and Mat Goldstein, have been selected as regional finalists in the EY Entrepreneur Of the Year® 2022 Ontario program. Selected by an independent panel of judges, Rebecca and Mat have been recognized for building a company that is transforming the capital markets and FinTech industries through inclusive innovation, sustainable growth, and democratizing prosperity. DealMaker is a disruptor in the capital markets and transforms the way leading brands raise private capital through technology. In just 4 years, DealMaker has powered over $1.5 Billion in capital raised for issuers; that’s more than double any leading US counterpart in less than half the operating history.
“It’s a great honour to be a finalist. Our mission has always been to innovate and digitize complex legal processes to democratize how capital is raised while increasing the access to invest to a wider audience” said Rebecca Kacaba, CEO, DealMaker. “None of this would have been possible without the dedication and hardwork of our entire international team at DealMaker. They bring our vision to life everyday and are allowing us to live our dream - we are extremely grateful.”
“I am very grateful for our team to receive this recognition from EY,” said co-founder Mat Goldstein, “We love what we do and it’s phenomenal for our remarkable team to receive this kind of external appreciation for all of their hard work and innovation.”
Issuers and organizations in the capital markets can learn more about DealMaker at https://www.dealmaker.tech/.
DealMaker is on a mission to create the most sophisticated capital markets tools on the planet, empowering capital to flow faster. It offers a suite of primary issuance, shareholder management, and capital raising solutions including investor ranking algorithms and data analytics tools to support all global private placements exemptions. Its innovative technology was designed to enable organizations to own and control exempt market raises to get the money they need, faster. DealMaker puts forward-thinking organizations in control to run streamlined, successful capital raises in one centralized platform. The company’s offices are located in Toronto, Canada, Austin, Texas and Tampa, Florida. Visit DealMaker.tech for more information.
News Links
When VCs said no, Monogram turned to retail investors. That decision powered their rise from startup to publicly traded company—and even helped them raise an additional $13M privately after their Nasdaq debut.
The Challenge: Raising Capital on Their Terms
The Challenge: Raising on Their Terms
Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.
Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?
- Control and ownership: Not only were they able to raise the capital they needed to grow the business—they did it on their own terms.
- Long-term asset: They wanted to build an army of true believers who wanted to see the company succeed and would continue to reinvest over the years.
- A value-add network: Raising from retail allowed Monogram to amass a waiting list of thousands of patients eager to participate in future trials.
- Aligned incentives: Their mission to improve patient outcomes and build a better future for those struggling with joint pain resonated with retail investors.
The Power of Retail: Monogram's Capital Journey
| Start Date | End Date | Type | Platform | Amount Raised | # Investors |
|---|---|---|---|---|---|
| 3/13/19 | 3/31/20 | A+ | SeedInvest | $14,588,668 | 6,000 |
| 11/16/20 | 1/16/21 | A+ | StartEngine | $2,965,501 | 8,000 |
| 1/17/21 | 2/18/22 | A+ | StartEngine | $23,647,853 | 14,082 |
| 7/15/22 | 3/16/23 | CF | DealMaker | $4,673,000 | 2,249 |
| 3/1/23 | 4/8/23 | A+ | Republic | $232,275 | 120 |
| 3/1/23 | 5/23/23 | A+ | DealMaker | $15,958,364 | 5,198 |
| 5/18/23 | - | Nasdaq listing | |||
| 7/24 | 10/24 | Unit Offering | DealMaker | $12,990,103 | 2,745 |
Monogram Capital Raise Timeline
Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.
Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.
$80M+
Raised across seven campaigns
~40,000
Investors championing Monogram's vision
20%
Of each raise came from previous investors
Marketing Excellence
DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.
Premium Publications
Targeted campaigns in premium publications like Morning Brew captured qualified investors
High-Engagement Webinars
Engaging events that generated over $4.3 million in investments
Community Building
Strategic approaches that fostered a loyal shareholder base
Investment Momentum
Innovative approaches that amplified investment momentum
Monogram's Journey to Success
Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:
- Filed its first patent application in 2017
- Conducted clinical studies at UCLA and University of Nebraska
- Expanded the team with key hires
- Attracted a top-tier advisory board to guide clinical innovations
- Signed their first distribution partnerships
- Made headlines with cutting-edge live demonstrations
- Secured 501(k) FDA clearance for the mBôs surgical system
Nasdaq Debut & Beyond
In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.
For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.
Public perception says you can't raise privately post-IPO. Monogram proved that wrong.
Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.
This was retail capital at its best: strategic, repeatable, and aligned.
One vision. Zero compromises.
This wasn't a one-time raise. It was a multi-year capital strategy.
Retail capital helped Monogram:
- Go from concept to commercialization without relying on VCs
- Retain ownership and control in a high-burn industry
- Build a base of loyal shareholders who invested not once, but over and over again
- Uplist to the Nasdaq, and still keep raising post-IPO
This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.
Ready to Raise Capital on Your Terms?
Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.
Explore Raising Capital with DealMaker.png)
.png)
Your submission has been received. We will reach out to you via email to schedule a call.
Oops! Something went wrong while submitting the form.